As far as I know, there's no evidence to suggest that pursuing the COVID indication contributed to the HIV BLA getting delayed.
If leronlimab can help people suffering from COVID, the choice to 'go for it' was correct, from both an ethical perspective and ultimately, IMO, from a shareholder's perspective.